CG Oncology, Inc. announced that it has received $105 million in funding from a group of investors

On August 2, 2023, CG Oncology, Inc. closed the transaction. The received oversubscribed $105,000,000 in a round of funding co-led by new investors, Foresite Capital Management, LLC, and TCG Crossover Management, LLC. The transaction included participation from new investors, Avidity Partners Management, L.P., BVF Partners L.P., Janus Henderson Investors US LLC, and returning investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital LLC, Longitude Capital Management Co., LLC, Malin Corporation plc, and RA Capital Management, L.P. The company issued 81,572,405 shares in the transaction.